Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Indomethacin · Indocin

Small molecule · Inhibitor of prostaglandin-endoperoxide synthase (cyclooxygenase) (PTGS2) · developed by Zyla Life Sciences

Approved FDA, Jun 1965
1 Registered trials

What is Indomethacin?

Indomethacin is a small-molecule drug that inhibits prostaglandin synthesis. It is used to close a patent ductus arteriosus in premature infants, and it is also studied in acute gout.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Indocin
Drug type
Small molecule
Targets
prostaglandin-endoperoxide synthase (cyclooxygenase) (PTGS2)
Mechanism
Inhibitor of prostaglandin-endoperoxide synthase (cyclooxygenase) (PTGS2)
Pathways
prostaglandin synthesis
Therapy area
Cardiovascular
Developer
Zyla Life Sciences
In trials of
OGN
FDA status
Approved as Indocin (June 10, 1965), NDA016059 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 16, 2023). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00142558 Phase 4 Acute Gout Completed OGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Gout

Other drugs acting on PTGS2

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.